Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials

被引：0
|
作者：
Paolo A. Ascierto
Antoni Ribas
James Larkin
Grant A. McArthur
Karl D. Lewis
Axel Hauschild
Keith T. Flaherty
Edward McKenna
Qian Zhu
Yong Mun
Brigitte Dréno
机构：
[1] Istituto Nazionale Tumori IRCCS Fondazione G. Pascale,
[2] Jonsson Comprehensive Cancer Center,undefined
[3] University of California at Los Angeles,undefined
[4] The Royal Marsden NHS Foundation Trust,undefined
[5] Peter MacCallum Cancer Centre,undefined
[6] University of Melbourne,undefined
[7] University of Colorado Comprehensive Cancer Center,undefined
[8] University Hospital Schleswig-Holstein,undefined
[9] Massachusetts General Hospital,undefined
[10] Genentech,undefined
[11] Inc.,undefined
[12] Nantes University,undefined
来源：
Journal of Translational Medicine | / 18卷
关键词：
Vemurafenib; Cobimetinib; Dacarbazine; Melanoma; Survival analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 20 条
  • [1] Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib±cobimetinib: a pooled analysis of four clinical trials
    Ascierto, Paolo A.
    Ribas, Antoni
    Larkin, James
    McArthur, Grant A.
    Lewis, Karl D.
    Hauschild, Axel
    Flaherty, Keith T.
    McKenna, Edward
    Zhu, Qian
    Mun, Yong
    Dreno, Brigitte
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)
  • [2] Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
    del Carmen Alamo, Ma
    Ochenduszko, Sebastian
    Crespo, Guillermo
    Corral, Monica
    Oramas, Juana
    Sancho, Pilar
    Medina, Javier
    Garicano, Fernando
    Lopez, Pedro
    Campos Balea, Begona
    Rodriguez Garzotto, Analia
    Munoz-Couselo, Eva
    ONCOTARGETS AND THERAPY, 2021, 14 : 5345 - 5352
  • [3] Validation of dabrafenib-trametinib prognostic groups in patients treated with vemurafenib and cobimetinib for advanced BRAF-mutated melanoma
    Sorich, Michael J.
    Rowland, Andrew
    Hopkins, Ashley M.
    MELANOMA RESEARCH, 2020, 30 (03) : 268 - 271
  • [4] Prognostic subgroups and impact of treatment for post-progression overall survival (ppOS) in patients (pts) with BRAFV600-mutated metastatic melanoma treated with dacarbazine (DTIC) or vemurafenib (VEM) ± cobimetinib (COBI): A pooled analysis
    Ascierto, P. A.
    Ribas, A.
    Larkin, J.
    McArthur, G. A.
    Lewis, K. D.
    Hauschild, A.
    Flaherty, K. T.
    McKenna, E.
    Zhu, Q.
    Mun, Y.
    Dreno, B.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] Impact of duration of response (DOR) on overall survival (OS) in patients with metastatic melanoma treated with dacarbazine (DTIC), vemurafenib (V), or cobimetinib plus vemurafenib (C plus V): a pooled analysis
    Lewis, K.
    Larkin, J.
    Ribas, A.
    Flaherty, K. T.
    McArthur, G. A.
    Ascierto, P. A.
    Dreno, B.
    McKenna, E.
    Zhu, Q.
    Mun, Y.
    Hauschild, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma Pooled Analysis of 4 Randomized Clinical Trials
    Hauschild, Axel
    Larkin, James
    Ribas, Antoni
    Dreno, Brigitte
    Flaherty, Keith T.
    Ascierto, Paolo A.
    Lewis, Karl D.
    McKenna, Edward
    Zhu, Qian
    Mun, Yong
    McArthur, Grant A.
    JAMA ONCOLOGY, 2018, 4 (10) : 1382 - 1388
  • [7] Correlating surrogate endpoints with overall survival at the individual patient level in BRAF-mutated metastatic melanoma patients treated with vemurafenib.
    Zabor, Emily Craig
    Heller, Glenn
    Schwartz, Lawrence H.
    Chapman, Paul B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials
    Ashley M. Hopkins
    Akash D. Rathod
    Andrew Rowland
    Ganessan Kichenadasse
    Michael J. Sorich
    BMC Cancer, 20
  • [9] Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials
    Hopkins, Ashley M.
    Rathod, Akash D.
    Rowland, Andrew
    Kichenadasse, Ganessan
    Sorich, Michael J.
    BMC CANCER, 2020, 20 (01)
  • [10] Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial data
    Hopkins, Ashley M.
    Van Dyk, Madele
    Rowland, Andrew
    Sorich, Michael J.
    PIGMENT CELL & MELANOMA RESEARCH, 2019, 32 (04) : 576 - 583
12